Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2006
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOGD Schadendorf, S Ugurel, B Schuler-Thurner, et al.
The British Journal of Dermatology|June 29, 2021
High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinomaD Westphal, M Garzarolli, M Sergon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2014
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survivalS Ugurel, C Loquai, K Kähler, et al.
The British Journal of Dermatology|February 18, 2020
GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanomaE Livingstone, A Zaremba, S Horn, et al.
ESMO Open|May 9, 2025
Early switch from run-in with targeted to immunotherapy in advanced BRAFV600-positive melanoma: final results of the randomised phase II ImmunoCobiVem trialE Livingstone, H J Gogas, L Kandolf, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2023
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trialE Livingstone, H Gogas, L Kandolf-Sekulovic, et al.
Pageof 6